SRZN
Surrozen, Inc.
NASDAQ · USHealthcareBiotechnology
$22.16+0.91%
Price as of Jul 20, 2026
SRZN financials
Surrozen, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $3.5M | $10.7M | $0.00 | $12.5M |
| Cost of revenue | $537.0K | $0.00 | $27.2M | $3.3M |
| Gross profit | $2.9M | $10.7M | -$27.2M | $9.2M |
| Operating expenses | $45.0M | $36.2M | $18.6M | $53.6M |
| Operating income | -$42.1M | -$25.5M | -$45.8M | -$44.3M |
| Net income | -$242.0M | -$63.6M | -$43.0M | -$36.0M |
| EBITDA | -$241.5M | -$62.1M | -$41.1M | -$34.0M |
| Basic EPS | $-32.37 | $-21.67 | $-21.33 | $-15.55 |
| Diluted EPS | $-32.37 | $-21.67 | $-21.33 | $-15.55 |
| Balance sheet | ||||
| Cash & equivalents | $89.2M | $34.6M | $36.0M | $24.7M |
| Total assets | $98.7M | $48.5M | $46.1M | $89.4M |
| Total liabilities | $286.5M | $69.8M | $8.1M | $13.4M |
| Stockholders’ equity | -$187.8M | -$21.4M | $37.9M | $76.0M |
| Total debt | $6.6M | $8.5M | $3.4M | $5.6M |
| Net debt | -$82.6M | -$26.1M | -$32.7M | -$19.1M |
| Cash flow | ||||
| Operating cash flow | -$30.2M | -$17.6M | -$40.4M | -$44.1M |
| Capital expenditure | -$128.0K | -$26.0K | -$398.0K | -$728.0K |
| Free cash flow | -$30.4M | -$17.7M | -$40.8M | -$44.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$4.0K | -$2.6M |